tecovirimat siga
siga technologies netherlands b.v. - tecovirimat - poxviridae infections; cowpox; monkeypox; vaccinia; smallpox - viirusevastased ravimid süsteemseks kasutamiseks - tecovirimat siga is indicated for the treatment of the following viral infections in adults and children with body weight at least 13 kg:- smallpox- monkeypox- cowpoxtecovirimat siga is also indicated to treat complications due to replication of vaccinia virus following vaccination against smallpox in adults and children with body weight at least 13 kg (see sections 4. 4 ja 5. tecovirimat siga should be used in accordance with official recommendations.
darzalex
janssen-cilag international n.v. - daratumumab - mitu müeloomit - monoclonal antibodies and antibody drug conjugates, antineoplastic agents - multiple myelomadarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. koos bortezomib, talidomiid ja deksametasooni raviks täiskasvanud patsientidel, kellel on äsja diagnoositud hulgimüeloom, kes vastavad tüvirakkude autoloogne siirdamine. koos lenalidomide ja deksametasoon või bortezomib ja deksametasooni, raviks täiskasvanud patsientidel, kellel on hulgimüeloom, kes on saanud vähemalt ühe eelneva ravi. in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5. kui monotherapy raviks täiskasvanud patsientidel, kellel on taastekkinud ja tulekindlad hulgimüeloom, kelle eelnev ravi sisaldas proteasome inhibiitor ja immuunmoduleerivad agent ja kes on näidanud haiguse progresseerumise viimasel ravi. al amyloidosisdarzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (al) amyloidosis.
gambrosol trio 10 peritoneaaldialüüsilahus
fresenius medical care deutschland gmbh - hüpertoonilised lahused - peritoneaaldialüüsilahus - 2000ml 1tk; 5000ml 1tk; 3000ml 1tk
gambrosol trio 40 peritoneaaldialüüsilahus
fresenius medical care deutschland gmbh - hüpertoonilised lahused - peritoneaaldialüüsilahus - 3000ml 1tk; 5000ml 1tk; 2000ml 1tk; 2500ml 1tk
lumeblue (previously known as methylthioninium chloride cosmo)
alfasigma s.p.a. - metüültioniiniumkloriid - colorectal neoplasms; colonoscopy - other diagnostic agents - lumeblue is indicated as a diagnostic agent enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy.
kolxip tablett
sandoz pharmaceuticals d.d. - esetimiib - tablett - 10mg 7tk; 10mg 14tk; 10mg 90tk; 10mg 60tk; 10mg 28tk; 10mg 20tk; 10mg 50tk; 10mg 10tk; 10mg 98tk
senstend
plethora pharma solutions limited - lidokaiin, prilocaine - enneaegne ejakulatsioon - anesteetikumid - senstend on näidustatud ravi esmase enneaegne ejakulatsioon täiskasvanud mehed.